Brentuximab vedotin—through CD30-targeted delivery of monomethyl auristatin E into Hodgkin Reed-Sternberg cells—has transformed the management of patients with classical Hodgkin's lymphoma, through both its high frequency and long duration of complete remission.¹ Since the initial approval of this agent, there has been high interest in its successful integration into earlier lines of management.^2–4

中文翻译：

---

Brentuximab vedotin治疗晚期霍奇金淋巴瘤

Brentuximab vedotin通过将CD30靶向的单甲基澳瑞他汀E传递到Hodgkin Reed-Sternberg细胞中，通过其高频率和长期完全缓解，已经改变了对经典Hodgkin淋巴瘤患者的治疗。¹自从该代理程序最初获得批准以来，人们对将其成功地集成到早期的管理部门中产生了浓厚的兴趣。^2–4